22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
At a time of crisis and economic upheaval, there is a natural tendency for people to pull together. ...
Read More >
The National Labor Relations Board (NLRB or the “Board”) has been steadily increasing employers’ ...
Read More >
In a recent publication, the Public Company Accounting Oversight Board (“PCAOB”) Staff shares some...
Read More >
Over the summer, we wrote about why health care companies may want to consider buying assets out of ...
Read More >
While the gig economy often gets derided by worker advocates for being unfair to its workers, one as...
Read More >
The Federal Trade Commission (FTC) announced on February 27 that it has filed an administrative comp...
Read More >